Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a paper Tom Powles and his colleagues authored on X:
“TROPiCS-04 trial out on Annals of Oncology: no statistical improvement in OS with the Trop2 ADC SG vs TPC in met urothelial cancer, with higher rate of G5 AEs with SG. Led to the withdrawal of SG approval for mUC. No association between Trop2 exp and SG activity.”
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Authors: Thomas Powles et al.
